Recently, the Liu Shen team has achieved favorable results across a series of pharmaceutical patent enforcement proceedings, covering multiple avenues including patent infringement litigation and administrative patent enforcement actions.

Upon being retained by the client, the Liu Shen team noted that multiple market players were exploiting the relevant patent rights without the patentee’s authorization. The team immediately engaged in close communication with the client’s technical experts, comprehensively collected evidence, formulated a tailored enforcement strategy, and promptly adopted multi-pronged enforcement measures to seize the initiative in all matters. The Liu Shen team successfully stopped infringing activities by multiple enterprises, fully fulfilled the client’s enforcement objectives, and secured reasonable compensation as expected, effectively upholding the client’s legitimate intellectual property rights and interests.

The biopharmaceutical industry is a key pillar of the national economy and a technology sector with high concentration of intellectual property assets. Pharmaceutical R&D represents a systematic project featuring high investment, high risks and long lead times, while patents serve as the final line of defense for biopharmaceutical enterprises to protect technological innovations and fend off infringement risks. This series of enforcement actions demonstrates the strength of China’s intellectual property protection system in safeguarding the biopharmaceutical industry, as well as its commitment to protecting public health and maintaining fair market competition order.

Led by Liu Shen Partner Stephen ZOU, and jointly handled by Lawyers ZHU Wenjing and CHANG Yuxuan, the enforcement work fully showcases the solid capability and profound expertise of Liu Shen’s IP service team in managing large-scale and complex IP enforcement series cases.